Oct 24 2025
Healthcare
Recent Research
CVS Group, FY2025 results
Oct 7 2025
hVIVO, H1 2025 results
Sep 23 2025
Malin Corporation, H1 results
Aug 27 2025
Meet your Healthcare Research team
CVS Group
Proposed change to listing and announcement of share buyback
CVS Group has announced that it intends to move from AIM to the main market of the London Stock Exchange. This is intended to give access to a deeper pool of capital. It has also...
CVS Group
FY2025 results
CVS’s FY2025 results reflect good revenue growth and margin expansion, especially given cost headwinds. Cash generation and proceeds from the sale of the Crematoria division have...
hVIVO
H1 2025 results
hVIVO has reported H1 results that are in line with expectations following its trading statement on July 22nd. The company has retained its guidance for FY2025. The industry has been...
Uniphar
H1 results reflect sharp acceleration in EPS growth
Uniphar grew its EPS by 21% in H1 2025. This is the company’s fastest rate of growth in several years and is driven by organic gross profit growth, accretion from its share buyback...
Malin Corporation
H1 results
Malin has reported its interim results to June 30th, showing an intrinsic equity value of €9.52/share. This has reduced slightly to €9.45/share at August 25th. This follows the €150m...
Uniphar
H1 2025 trading statement drives further upgrades
Uniphar has issued a trading statement ahead of its H1 2025 results, which will be published on September 2nd. All divisions are performing strongly with c.8% organic gross profit growth....
CVS Group
FY2025 trading statement is in line with expectations
CVS has issued a trading statement for FY2025 to June 30th. Revenues are close to our forecast and were impacted by weak market conditions in the UK. EBITDA is in line with our...
hVIVO
H1 trading statement
hVIVO has issued a trading statement for H1, reiterating FY2025 revenue guidance and indicating a slight improvement in the outlook for EBITDA. The sector remains challenged due to...
hVIVO
Trading update
hVIVO has announced that it has received notification of a significant contract cancellation alongside a postponement and a cancellation of a smaller study. This is due to uncertainty in...
Uniphar
AGM statement
Uniphar will have its AGM later this morning. Ahead of that, the company has confirmed that its capex programmes remain on track, it has reiterated its medium-term EBITDA target,...
